Hear how the FDA Center for Drug Evaluation and Research (CDER) Nexus Program is harnessing the speed and flexibility of Appian’s low-code automation platform to modernize and accelerate their drug application review and safety monitoring processes. CDER is moving to a scalable cloud-based workflow platform with reusable components while employing agile practices to quickly release new applications.
Speaker
Jonathan Rappaport, Director, Division of Regulatory Review and Drug Safety Services and Solutions, FDA